… trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine … , MD, Professor of Medicine, Clinical Director, Transplant … date in clinical trials of different cancers, … and immunosuppressive barrier to cancer treatment; (2) SYN-004 …

… drug for the treatment of IPF has entered clinical trials … delivery systems, requiring detailed pharmaceutical, non-clinical, and clinical … versus gemcitabine plus cisplatin in the first-line treatment of … target gene knockdown. Nat Biotechnol. 2015;33(8):970 …

… , about the FDA approval of the gemcitabine intravesical system (formerly … TAR-200; Inlexzo)​ for the treatment … of New York Upstate Medical University in Syracuse. In … phase 2b SunRISe-1 trial (NCT04640623), and the …

… (Zusduri)—are shaping treatment strategies aimed at reducing … alternatives—most commonly gemcitabine or gemcitabine-docetaxel combinations—as … 3 ENVISION trial (NCT05243550), which led to FDA approval of … as cost approval and medication access. In some systems …

… shifting to intravesical chemotherapy—typically gemcitabine, with or without docetaxel—for … may complicate treatment. Access and cost were recurring themes. Although Medicare coverage … TURBT, noting that although the drug’s list price is substantial …

… -GemOx group, with treatment duration advantages observed in … -label, multicenter, global trial assessing the efficacy and … polatuzumab vedotin, an antibody-drug conjugate (ADC), in patients … Rituximab in Combination With Gemcitabine Plus Oxaliplatin in …

… given to only one medical doctor per annum, the … Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical … approach to targeted treatment offers the potential … RenovoCath with gemcitabine received Orphan Drug Designation for …

… therapeutic approaches. However, biotechnology and nanomedicine advances are … II trial assesses SGT-53 combined with gemcitabine… and clinical trials to enhance drug delivery effectiveness. … for targeted treatment of glioblastoma. Pharmaceutics. 2024;16 …

… Biotech’s topical gene therapy Vyjuvek received a FDA … clinical trials. The Chinese National Medical Products … drug, excluding in the U.S., through a November 2024 deal with ARS Pharmaceuticals … drugs gemcitabine and cisplatin for initial treatment of adults …

… cancer Combining cambritaxestat with gemcitabine/nab-paclitaxel ( … no treatment-emergent adverse events (TEAE) leading to drug … Dr. Michael Lahn, Chief Medical Officer at iOnctura said, … .S. Food and Drug Administration (FDA), in March 2024. …